Does the media prefer PURR or LYEL?

In the previous week, Lyell Immunopharma had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 6 mentions for Lyell Immunopharma and 3 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.35 beat Lyell Immunopharma's score of 0.23 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AMLX or LYEL?

In the previous week, Lyell Immunopharma had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 6 mentions for Lyell Immunopharma and 4 mentions for Amylyx Pharmaceuticals. Lyell Immunopharma's average media sentiment score of 0.23 beat Amylyx Pharmaceuticals' score of 0.12 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ANAB or LYEL?

In the previous week, Lyell Immunopharma had 4 more articles in the media than AnaptysBio. MarketBeat recorded 6 mentions for Lyell Immunopharma and 2 mentions for AnaptysBio. Lyell Immunopharma's average media sentiment score of 0.23 beat AnaptysBio's score of -0.82 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Lyell Immunopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VIR or LYEL?

In the previous week, Vir Biotechnology had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 10 mentions for Vir Biotechnology and 6 mentions for Lyell Immunopharma. Vir Biotechnology's average media sentiment score of 0.38 beat Lyell Immunopharma's score of 0.23 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lyell Immunopharma (LYEL) Competitors

$12.31 +0.34 (+2.84%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$12.30 -0.01 (-0.04%)

As of 06/8/2026 07:39 PM Eastern

Compare

LYEL vs. PURR, AMLX, ANAB, DMRA, and VIR

Should you buy Lyell Immunopharma stock or one of its competitors? MarketBeat compares Lyell Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyell Immunopharma include Hyperliquid Strategies (PURR), Amylyx Pharmaceuticals (AMLX), AnaptysBio (ANAB), Damora Therapeutics, Inc. Common Stock (DMRA), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.

How does Lyell Immunopharma compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Hyperliquid Strategies has higher revenue and earnings than Lyell Immunopharma. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,288.49	-$16.01M	-$7.37	N/A
Lyell Immunopharma	$31K	9,265.86	-$274.45M	-$13.80	N/A

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lyell Immunopharma had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 6 mentions for Lyell Immunopharma and 3 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.35 beat Lyell Immunopharma's score of 0.23 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperliquid Strategies presently has a consensus target price of $9.25, indicating a potential upside of 3.70%. Lyell Immunopharma has a consensus target price of $43.00, indicating a potential upside of 249.31%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Hyperliquid Strategies has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Hyperliquid Strategies' return on equity of -56.04% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Summary

Hyperliquid Strategies beats Lyell Immunopharma on 9 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Amylyx Pharmaceuticals currently has a consensus price target of $23.00, indicating a potential upside of 76.79%. Lyell Immunopharma has a consensus price target of $43.00, indicating a potential upside of 249.31%. Given Lyell Immunopharma's higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amylyx Pharmaceuticals has higher revenue and earnings than Lyell Immunopharma. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	16.56	-$144.74M	-$1.50	N/A
Lyell Immunopharma	$31K	9,265.86	-$274.45M	-$13.80	N/A

In the previous week, Lyell Immunopharma had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 6 mentions for Lyell Immunopharma and 4 mentions for Amylyx Pharmaceuticals. Lyell Immunopharma's average media sentiment score of 0.23 beat Amylyx Pharmaceuticals' score of 0.12 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

AnaptysBio presently has a consensus target price of $79.18, indicating a potential upside of 54.17%. Lyell Immunopharma has a consensus target price of $43.00, indicating a potential upside of 249.31%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

AnaptysBio has a net margin of -11.53% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

66.1% of Lyell Immunopharma shares are held by institutional investors. 33.5% of AnaptysBio shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lyell Immunopharma had 4 more articles in the media than AnaptysBio. MarketBeat recorded 6 mentions for Lyell Immunopharma and 2 mentions for AnaptysBio. Lyell Immunopharma's average media sentiment score of 0.23 beat AnaptysBio's score of -0.82 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Lyell Immunopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Lyell Immunopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.37	-$13.23M	-$1.08	N/A
Lyell Immunopharma	$31K	9,265.86	-$274.45M	-$13.80	N/A

Summary

AnaptysBio beats Lyell Immunopharma on 9 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Lyell Immunopharma. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Lyell Immunopharma	$31K	9,265.86	-$274.45M	-$13.80	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $42.00, suggesting a potential upside of 100.86%. Lyell Immunopharma has a consensus price target of $43.00, suggesting a potential upside of 249.31%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Lyell Immunopharma had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Lyell Immunopharma and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.50 beat Lyell Immunopharma's score of 0.23 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Positive
Lyell Immunopharma	Neutral

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Damora Therapeutics, Inc. Common Stock and Lyell Immunopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Vir Biotechnology has a net margin of -638.88% compared to Lyell Immunopharma's net margin of -794,858.12%. Vir Biotechnology's return on equity of -53.31% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vir Biotechnology currently has a consensus price target of $20.38, indicating a potential upside of 141.12%. Lyell Immunopharma has a consensus price target of $43.00, indicating a potential upside of 249.31%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Vir Biotechnology had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 10 mentions for Vir Biotechnology and 6 mentions for Lyell Immunopharma. Vir Biotechnology's average media sentiment score of 0.38 beat Lyell Immunopharma's score of 0.23 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lyell Immunopharma has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	20.79	-$437.99M	-$3.13	N/A
Lyell Immunopharma	$31K	9,265.86	-$274.45M	-$13.80	N/A

Vir Biotechnology has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

Summary

Vir Biotechnology beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$279.31M	$2.96B	$6.48B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-0.89	17.68	23.69	23.74
Price / Sales	9,265.86	302.68	514.83	109.27
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	1.05	3.83	10.43	6.78
Net Income	-$274.45M	$75.85M	$3.57B	$337.51M
7 Day Performance	-17.33%	-2.00%	0.27%	-2.34%
1 Month Performance	-36.32%	-5.85%	3.25%	1.88%
1 Year Performance	-1.28%	14.03%	22.24%	25.55%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	2.9194 of 5 stars	$12.31 +2.8%	$43.00 +249.3%	-3.5%	$279.31M	$31K	N/A	270	News Coverage Analyst Forecast
PURR Hyperliquid Strategies	1.6385 of 5 stars	$10.97 +0.9%	$9.25 -15.7%	N/A	$1.57B	$1M	N/A	N/A
AMLX Amylyx Pharmaceuticals	2.622 of 5 stars	$13.29 -5.5%	$23.00 +73.1%	+144.1%	$1.56B	$87.37M	N/A	200	News Coverage Analyst Forecast
ANAB AnaptysBio	2.7 of 5 stars	$51.26 -3.5%	$79.18 +54.5%	+116.7%	$1.55B	$234.60M	N/A	100	Gap Up
DMRA Damora Therapeutics, Inc. Common Stock	2.7167 of 5 stars	$22.95 -7.6%	$42.00 +83.0%	+535.6%	$1.53B	N/A	N/A	40	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. PURR, AMLX, ANAB, DMRA, and VIR

How does Lyell Immunopharma compare to Hyperliquid Strategies?

Summary

How does Lyell Immunopharma compare to Amylyx Pharmaceuticals?

Summary

How does Lyell Immunopharma compare to AnaptysBio?

Summary

How does Lyell Immunopharma compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Lyell Immunopharma compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. PURR, AMLX, ANAB, DMRA, and VIR

How does Lyell Immunopharma compare to Hyperliquid Strategies?

Which has more risk and volatility, PURR or LYEL?

Which has higher valuation and earnings, PURR or LYEL?

Do insiders & institutionals hold more shares of PURR or LYEL?

Does the media prefer PURR or LYEL?

Do analysts rate PURR or LYEL?

Is PURR or LYEL more profitable?

Summary

How does Lyell Immunopharma compare to Amylyx Pharmaceuticals?

Is AMLX or LYEL more profitable?

Do analysts recommend AMLX or LYEL?

Do insiders and institutionals hold more shares of AMLX or LYEL?

Which has preferable valuation & earnings, AMLX or LYEL?

Does the media prefer AMLX or LYEL?

Which has more risk and volatility, AMLX or LYEL?

Summary

How does Lyell Immunopharma compare to AnaptysBio?

Do analysts recommend ANAB or LYEL?

Is ANAB or LYEL more profitable?

Do insiders & institutionals hold more shares of ANAB or LYEL?

Does the media prefer ANAB or LYEL?

Which has more risk & volatility, ANAB or LYEL?

Which has stronger earnings and valuation, ANAB or LYEL?

Summary

How does Lyell Immunopharma compare to Damora Therapeutics, Inc. Common Stock?

Is DMRA or LYEL more profitable?

Which has stronger valuation & earnings, DMRA or LYEL?

Which has more volatility and risk, DMRA or LYEL?

Do analysts rate DMRA or LYEL?

Does the media prefer DMRA or LYEL?

Do institutionals and insiders hold more shares of DMRA or LYEL?

Summary

How does Lyell Immunopharma compare to Vir Biotechnology?

Is VIR or LYEL more profitable?

Do institutionals and insiders believe in VIR or LYEL?

Do analysts rate VIR or LYEL?

Does the media refer more to VIR or LYEL?

Which has preferable valuation & earnings, VIR or LYEL?

Which has more volatility and risk, VIR or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools